April 14, 2025 a 03:31 pm
Moderna, Inc. is a leader in biotechnology, renowned for its innovative mRNA-based therapeutics and vaccines targeting a broad array of diseases. While its pioneering work, especially in respiratory vaccines, positions it well in the healthcare industry, investors should consider its fluctuating financial ratios and market volatility. The stock presents both potential high returns and risks, making it crucial for investors to monitor its strategic developments closely.
Fundamental Rating
Moderna, Inc. has shown a balanced performance across various fundamental metrics. Below are the current ratings:
| Category | Score | Bar |
|---|---|---|
| Discounted Cash Flow | 3 | |
| Return On Equity | 1 | |
| Return On Assets | 1 | |
| Debt To Equity | 3 | |
| Price To Earnings | 1 | |
| Price To Book | 3 |
Historical Rating
The historical performance of Moderna reflects shifts in overall scores. Below is a snapshot of the past ratings:
| Date | Overall | DCF | ROE | ROA | Debt/Equity | P/E | P/B |
|---|---|---|---|---|---|---|---|
| 2025-04-11 | 2 | 3 | 1 | 1 | 3 | 1 | 3 |
| Previous Date | 0 | 3 | 1 | 1 | 3 | 1 | 3 |
Analyst Price Targets
Analysts have varied opinions on Moderna's stock, projecting a range of future valuations:
| High | Low | Median | Consensus |
|---|---|---|---|
| $69 | $45 | $55 | $55.33 |
Analyst Sentiment
Analysts have offered the following recommendations for Moderna:
| Recommendation | Count | Bar |
|---|---|---|
| Strong Buy | 0 | |
| Buy | 9 | |
| Hold | 9 | |
| Sell | 1 | |
| Strong Sell | 0 |
Conclusion
Moderna, Inc. is a pivotal player in the biotech sector, offering promising growth prospects through its mRNA technologies. While its fundamentals reflect moderate stability, the company's stock has potential for both reward and volatility. Investors should weigh the innovation-driven growth against market risks. Analyst sentiment largely supports a 'Buy' consensus, but close attention should be paid to market trends and strategic developments. It's crucial to balance the observed scores with potential long-term benefits.